Kiora Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Kiora Pharmaceuticals

09/05/2025 14:01

Kiora Pharmaceuticals Inc KPRX.OQ reported a quarterly adjusted loss of 52 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $3.42.  The mean expectation of two analysts for the quarter was for a loss of 67 cents per share. Wall Street expected results to range from -77 cents to -57 cents per share.

Reported revenue was zero​; analysts expected $750.00 thousand.

Kiora Pharmaceuticals Inc's reported EPS for the quarter was a loss of 52 cents​.

The company reported a quarterly loss of $2.19 million.

Kiora Pharmaceuticals Inc shares had risen by 3.7% this quarter and lost 5.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Kiora Pharmaceuticals Inc is $11.00

This summary was machine generated from LSEG data May 9 at 01:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.67
-0.52
Beat
Dec. 31 2024
-0.55
-1.04
Missed
Sep. 30 2024
-0.76
-0.81
Missed
Jun. 30 2024
-0.86
-0.53
Beat